Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
 |
Voice of America - July 20, 2009
Joe DeCapua
Washington D.C.
A shift in priorities is blamed for the first ever decline in funding for AIDS vaccine research. The finding appears in a report published Monday called Adapting to Realities: Trends in HIV Prevention Research Funding 2000 to 2008.
The study was released in Cape Town, South Africa, at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. It was put out by the HIV Vaccine and Microbicide Resource Tracking Working Group, which includes the AIDS Vaccine Advocacy Coalition (AVAC), the International AIDS Vaccine Initiative (IAVI), UNAIDS and others.
Mitchell Warren, head of AVAC, is attending the conference in Cape Town.
"We have been for the last eight years tracking investments in AIDS vaccines," he says. "We've seen steady gains year by year.... But 2008 represents the first time that there's been a decrease in investment, specifically in preventive HIV vaccines."
Funding for AIDS vaccine research has declined, according to the report, dropping from around $930 million to $870 million.
Priority shift
"The biggest decline actually comes from the pharmaceutical sector, the commercial investment," he says.
Merck has been a leader in AIDS vaccine research funding in the commercial sector. However, one of its vaccine candidates fared poorly in trials in 2007.
"Although they are still very much involved in the effort to understand why it didn't work...they're not making the kind of financial investments that they had previously," he says.
Besides the decline in funding from Merck, there's been a shift toward basic science research.
"There's a great deal of work to try to understand why the Merck vaccine didn't work and how to make better vaccines.... But that tends to happen in more of the basic science and pre-clinical research," he says.
Positives and negatives
"From a realignment point of view, in terms of funding shifting from product development to basic science, it's exactly the right kind of thing that needs to happen.... The bad thing is the change in funding amounts. We need to ensure that when products don't work we don't see downturns in funding," he says.
Warren says there has been an increase in funding for microbicides and the use of anti-retroviral drugs as preventive measures. Microbicides are gels or creams that could be used as preventive to HIV infection during sex. But so far, no product has proven effective. As for the anti-retroviral drugs, they might be used by HIV-negative people to prevent infection.
090720
VA090706
Copyright © 2009 - Voice of America. You are welcome to use any material that is published by voanews.com, or you may link to any of the web pages that Voice of America has published on the internet. There is no need to request further permission. Should you wish to establish a link to any VOA web pages, please send your request to pubaff@ibb.gov. We would appreciate that credit for any use of VOA material be given to voanews.com, Voice of America, or VOA, and we ask that you not abridge or edit any VOA material which you may use.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .